Active Stocks

Fri May 16 2025 15:57:25

Bharti Airtel share price
1,814.35 -2.81%

Tata Motors share price
730.70 0.36%

Icici Bank share price
1,453.65 0.19%

Tata Steel share price
157.45 0.06%

Indusind Bank share price
782.30 0.26%

Business News > Mint Authors > David Wainer

David Wainer

Mint Author

ARTICLES BY DAVID WAINER

US President Donald Trump. (AP)

Trump’s drug price crackdown, like his trade war, could be more bark than bite

4 min read . 13 May 2025

In the past two weeks, as prescription volumes have remained sluggish, analysts cut first-quarter sales estimates for Wegovy by about 5%. (REUTERS)

Why new Wegovy deals won’t restore Novo Nordisk’s obesity lead

3 min read . 30 Apr 2025

Pfizer is among the drug companies that have managed to pay little in income tax in the U.S.

How Trump’s tariffs could upend pharma’s overseas tax strategy

4 min read . 02 Apr 2025

Though Gilead has struggled for years to find momentum, its stock has climbed 21% in 2025. Photo: Jason Henry for WSJ

Drug stocks are the new safe bet in a shaky market

3 min read . 28 Feb 2025

China’s rise in biotech has been years in the making, but it is now impossible to ignore. (Image: Pixabay)

The drug industry is having its own DeepSeek moment

4 min read . 07 Feb 2025

After analyzing data going back to 2016, one analyst thinks he has identified a seasonal pattern in demand for drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. (REUTERS)

Are weight-loss drugs like gym memberships? The answer is worth billions

3 min read . 29 Jan 2025

Pfizer CEO Albert Bourla said the prior administration was influenced by progressive priorities. (Reuters)

Beaten down under Biden, big pharma hopes for new chapter under Trump

3 min read . 20 Jan 2025

Eli Lilly’s Mounjaro weight-loss drug. Photo: Bloomberg News

Eli Lilly and Novo Nordisk’s obesity moat just got stronger

3 min read . 01 Dec 2024

Novo Nordisk Ozempic pens Photo: Charlotte de la Fuente for WSJ

Eli Lilly and Novo want to shake off Ozempic copycats. Will they meet demand?

1 min read . 18 Nov 2024

Pens for the diabetes drug Ozempic. (Image: Reuters)

Big Pharma’s obesity bonanza faces new tests

4 min read . 04 Nov 2024

There are signs that Pfizer CEO Albert Bourla is being attentive to Wall Street critics. Photo: John Scrivener for WSJ

Pfizer CEO’s job is at risk. A shot of discipline could help.

3 min read . 08 Oct 2024

Xanomeline is part of a class of drugs that target muscarinic receptors in the brain, which play a crucial role in various cognitive functions, including memory, mood and emotion. (Image: Pixabay)

Old drug repurposed for Schizophrenia could reap Alzheimer’s windfall

3 min read . 07 Oct 2024

Bob Duggan’s latest investment has become one of the industry’s greatest bets in recent years. (Shelley D. Spray)

How a surfer who never finished college became a biotech billionaire

5 min read . 23 Sep 2024

At this juncture in a drug or medical product’s development, rivals usually keep quiet or say something generic about how it is good to have more options for patients while cautioning that more data are needed.

The battle brewing over blood tests for cancer

2 min read . 17 Sep 2024

As Covid vaccine sales decline precipitously, Moderna’s roughly $4.5 billion in annual research-and-development spending is simply too high (File Photo)

Pandemic darling Moderna needs a reality check

3 min read . 06 Sep 2024

The short-term overhang might be gone, but the long-term risk for pharma is still very much present. (AP)

The Feds are ‘playing nice’ with pharma, at least for now

2 min read . 16 Aug 2024

Eli Lilly’s GLP-1 medications including Zepbound beat analysts’ estimates. (REUTERS)

Eli Lilly is gaining on Novo Nordisk in the obesity race

3 min read . 09 Aug 2024

For the past few years, pharma companies have been warning that they might need to cut back on innovation as the U.S. government forces some companies to negotiate prices of their top-selling drugs. (Image: Pixabay)

Big pharma cuts R&D, sending shudders through industry

2 min read . 08 Aug 2024

Eli Lilly benefited from the GLP-1 craze. (REUTERS)

Big Pharma rallies and moves past obesity

3 min read . 29 Jul 2024

A box of Ozempic and contents. (File Photo: Reuters)

Rivals emerge to Ozempic and Zepbound—but with a lag

3 min read . 19 Jul 2024